Compositions and methods for treating b cell mediated autoimmune disorders
OwnerDonald HEALEY, Lauren COLLISONinventors
Life of this patent
Estimating the term…
Abstract
Provided herein are methods, kits, compositions and uses related to the treatment of a B cell mediated autoimmune disorder with a T cell vaccine comprising a therapeutically effective amount of T cells autologous to the patient and that react to an autoantigen or specific epitope(s) thereof associated with the B cell mediated autoimmune disorder, wherein the treatment is provided to a patient in need thereof having suppressed B cell immune responses.
Claims42
A composition comprising at least one human T cell line comprising human T cells specific for an autoantigen associated with a B cell mediated immune disorder.
The composition of any of the preceding claims, wherein the B cell mediated autoimmune disorder is an organ specific B cell mediated autoimmune disorder.
The composition of any of the preceding claims, wherein the B cell mediated autoimmune disorder is selected from the group consisting Grave's disease, Hashimoto's Thyroiditis, immune thrombocytopenic purpura (ITP), Myasthenia Gravis, neuromyelitis optica (NMO), Pemphigus vulgaris, Pemphigus foliaceus, and primary biliary cirrhosis.
The composition of any one of the preceding claims, wherein the B cell mediated autoimmune disorder is neuromyelitis optica and the human T cells recognize aquaporin-4 or an epitope thereof.
The composition of any one of the preceding claims, wherein the B cell mediated autoimmune disorder is immune thrombocytopenic purpura and the human T cells are activated with platelet integrin glycoprotein IIb/IIIa or one or more immunostimulatory epitopes thereof.
The composition of any one of the preceding claims, wherein the T cells are attenuated, and wherein the composition comprises an amount of the attenuated T cells effective to suppress T cell responses against the autoantigen in a patient with the B cell mediated autoimmune disorder.
A method for making the composition of any one of the preceding claims comprising obtaining a T cell line specific for an autoantigen or epitope thereof associated with a B cell mediated autoimmune disorder by expanding T cells isolated from a patient to be treated with the autoantigen or epitope thereof.
The method of method of 16, wherein each fragment in the mixture is 12-16 amino acids and comprises an overlapping sequence of 8-12 amino acids with another fragment in the mix.
Use of a T cell vaccine comprising a therapeutically effective amount of autologous and attenuated T cells that are reactive to an autoantigen associated with a B cell mediated autoimmune disorder in the manufacture of a medicament for the treatment of a B cell mediated autoimmune disorder in a patient in need thereof and having suppressed B cell mediated immune responses.
Dependencies are inferred from the claim text.